Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Malignant Melanoma: early-phase trial registry
7 of 29 indexed Malignant Melanoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #552 of 28,707 conditions by registered trial count.
29 US clinical trials · 7 currently recruiting · #552 of 28,707 conditions by registered trial count
Malignant Melanoma: 29 US clinical trials tracked, 7 recruiting.
Malignant Melanoma is the subject of 29 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most active sponsor is Hoffmann-La Roche, running 3 of these trials.
Enrollment posture brief
Registry condition malignant-melanoma
OPEN 7 | RECR 24% | LATE 2 | EARLY 24 | RANK #552 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Burnout, Professional (24% recruiting · 29 trials)
Malignant Melanoma lists 7 open slots (24% of 29 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Malignant Melanoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Malignant Melanoma is recruiting below its size-band peers.
7 of 29 indexed trials (24.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Malignant Melanoma trials is spread across many organizations.
Hoffmann-La Roche accounts for 3 of 29 trials (10.3%). 26 distinct sponsors appear on at least one study for this condition label.
-
Most Malignant Melanoma trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 29 trials that report a genuine target (sentinel values excluded). 21 of those (72.4%) plan for fewer than 100 participants.
-
Malignant Melanoma research is mostly interventional.
28 interventional and 1 observational studies make up this index (96.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
29 total, page 1 of 1
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
VastBiome
NCT05037825
A Clinical Study of V940 and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Merck Sharp & Dohme
NCT06961006
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
LG Chem
NCT06332755
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Compass Therapeutics
NCT06150664
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
BioEclipse Therapeutics
NCT04282044
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Y-mAbs Therapeutics
NCT05130255
RAPA-201 Therapy of Solid Tumors
Rapa Therapeutics
NCT05144698
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
St. Jude Children's Research Hospital
NCT00539591
Phase Ib of L-NMMA and Pembrolizumab
The Methodist Hospital Research Institute
NCT03236935
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
Pfizer
NCT06974734
Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma
University of Colorado, Denver
NCT05089370
SciBase International Melanoma Pivotal Study
SciBase AB
NCT01077050
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Celgene
NCT00864253
A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma
Hoffmann-La Roche
NCT01689519
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Pfizer
NCT01307267
Phase II Trial of Allovectin-7® for Metastatic Melanoma
Vical
NCT00044356
A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
Hoffmann-La Roche
NCT01271803
Comparison of Video-Based Versus Written Patient Education on Melanoma
University of California, Davis
NCT00826995
A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma
Hoffmann-La Roche
NCT01107418
GM-CSF as Adjuvant Therapy of Melanoma
Northern California Melanoma Center
NCT00350597
A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Takara Bio
NCT02272855
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
Bristol-Myers Squibb
NCT00441337
Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma
Regeneron Pharmaceuticals
NCT03084640
An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma
Eli Lilly and Company
NCT01137006
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
Cantargia AB
NCT04452214
Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma
MedImmune
NCT00111696
In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer
Beth Israel Deaconess Medical Center
NCT00631072
Vaccine Treatment for Advanced Malignant Melanoma
NewLink Genetics Corporation
NCT00300612
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
Gradalis
NCT02574533
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 19 |
| Phase 2 | 5 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Malignant Melanoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Malignant Melanoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Malignant Melanoma page
29 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Malignant Melanoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Hoffmann-La Roche sponsors the most Malignant Melanoma trials on record, review their full trial history before evaluating a specific study. See Hoffmann-La Roche's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malignant Melanoma condition card totals 29 registered trials; most-linked intervention Pembrolizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.